Follow Us GraphicFacebook IconTwitter IconLinkedIn Icon
Search Graphic

Expert Financial Analysis and Reporting

Northwest Biotherapeutics and Agenus: What Are The Implications for These Companies in the Aftermath of Two Recent Cancer Vaccine Trial Failures? (NWBO, $0.38, Buy) (AGEN, $3.99, Buy)

Two Recent Cancer Vaccine Trial Failures Spurred this Report

On February 22, 2017, Argos reported that the Data Monitoring Committee for…
Read more…

Agenus: Update on Drug Development Programs (AGEN; Buy, $5.65)

Investment Thesis

This report focuses on product development efforts discussed in Agenusí 2Q, 2016 conference call. My most likely investment scenario…
Read more…

Comments on Agenus and Antares

SmithOnStocks Mailbox
About the Mailbox:

My mailbox comments are brief articles on stocks in which I am involved. These can come from…
Read more…

Agenus: Encouraging Data on Prophage, But What is the Path Forward (AGEN, Buy, $3.28)

Introduction

On July 1, Agenus announced results from a non-randomized, phase 2 study of its therapeutic cancer vaccine Prophage in newly…
Read more…